Newscasting from ESC 2024: SEQUOIA-HCM Substudy Details Effects of Aficamten on Cardiac Structure and Remodeling
Leading up to an expected US Food and Drug Administration submission, which Cytokinetics expressed will be filed before the close of Q3 2024, new data at the European Society of Cardiology (ESC) Congress 2024 details the effects of aficamten from the cardiac magnetic resonance (CMR) substudy in SEQUOIA-HCM.
Presented at Heart Failure 2024 and simultaneously published in the New England Journal of Medicine, the 24-week phase 3 SEQUOIA-HCM trial enrolled 282 patients with obstructive hypertrophic cardiomyopathy (HCM), with 142 randomized to aficamten and 140 randomized to placebo.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
